Ocata Therapeutics Announces New Pre-Clinical Data to be Reported at the International Congress on Systemic Lupus Erythematosus

Promising Potential Therapeutic Activity from the Company’s Proprietary HMC™ Platform to be presented in Vienna, Austria on September 4, 2015

MARLBOROUGH, Mass.--()--Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ:OCAT), a leader in the field of Regenerative OphthalmologyTM, announced today that data will be presented at the 11th International Congress on Systemic Lupus Erythematosus, taking place in Vienna, Austria from September 2-6.

The results demonstrate promising potential therapeutic activity of a pluripotent stem cell-derived product for the treatment of autoimmune diseases such as lupus nephritis and Crohn's disease using Ocata’s proprietary Hemangio-derived Mesenchymal Cell (HMCTM) platform. This unique and proprietary HMC product has been shown to have highly potent immune-modulatory and anti-inflammatory activity and is potentially well-suited for commercial scale up with retention of therapeutic potency.

The data describes both ex-vivo and in-vivo evidence in a highly regarded pre-clinical model of lupus nephritis. Top line data supports a prior proof-of-concept study which showed that HMC treatment increased the lifespan of the lupus-prone mice. The current study expands upon the initial results and examines how HMCs significantly inhibit the progression of otherwise fatal glomerulonephritis. The abstract will be presented at the Vienna Congress Center on Friday, September 4, 2015.

“This presentation at the leading lupus meeting is an important first step in developing potential new breakthrough treatments for disabling autoimmune diseases like lupus nephritis, where there is no cure available today,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer. “Our preclinical research and patent estate firmly anchors our leading position in the development of this novel Restorative Immunology™ platform and gives Ocata the ability to partner the non-ophthalmic uses of its technology for the treatment of devastating autoimmune diseases.”

About Ocata Therapeutics, Inc.

Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of regenerative ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs. For more information, visit www.ocata.com.

Forward-Looking Statements

All statements, other than historical facts, contained in this news release, including statements regarding Ocata’s belief regarding the potential therapeutic activity of a pluripotent stem cell-derived product in the treatment of auto immune diseases using Ocata’s proprietary HMC platform, Ocata’s belief that its HMC product is well-suited for commercial scale up and its retention of therapeutic potency, the effect of Ocata’s pre-clinical research and patent estate on the development of its product platforms, and any other statements about Ocata’s future expectations, beliefs, goals, plans, results or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: the fact that Ocata has no product revenue and no products approved for marketing; Ocata’s limited operating history; Ocata’s need for and limited sources of future capital; potential failures or delays in obtaining regulatory approval of products; risks inherent in the development and commercialization of potential products; reliance on new and unproven technology in the development of products; the need to protect Ocata’s intellectual property; the challenges associated with conducting and enrolling clinical trials; the risk that the results of clinical trials may not support Ocata’s product candidate claims; the risk that physicians and patients may not accept or use Ocata’s products, even if approved; Ocata’s reliance on third parties to conduct its clinical trials and to formulate and manufacture its product candidates; and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Ocata’s periodic reports, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2014. Forward-looking statements are based on the beliefs, opinions, and expectations of Ocata’s management at the time they are made, and Ocata does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of Ocata’s management at the time they are made, and Ocata does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that Ocata’s future clinical trials will be successful or that the results of previous clinical studies will lead to commercialization or products or therapies.

Contacts

Ocata Therapeutics, Inc.
Investors:
Westwicke Partners
John Woolford, 443-213-0506
john.woolford@westwicke.com
or
Press:
Russo Partners
David Schull, 858-717-2310
david.schull@russopartnersllc.com

Contacts

Ocata Therapeutics, Inc.
Investors:
Westwicke Partners
John Woolford, 443-213-0506
john.woolford@westwicke.com
or
Press:
Russo Partners
David Schull, 858-717-2310
david.schull@russopartnersllc.com